Peru’s Health Minister, Silvia Pessah, after announcing the first case of price-fixing agreements for the public purchase of medicines in Peru, has now also revealed that three other similar cases have been identified, which have already been notified to the corresponding authority.
Price manipulation was detected in several products, whose prices for the State appear to have risen significantly and without justification. In one example, Pessah details that a surcharge of over 10 times was discovered for a drug when compared with prices in commercial pharmacies.
As a measure, Pessah also announced that the Ministry of Health (MINSA) would stop buying some of the affected medications, launching a new round of contracts to ensure fair prices. Affected medications include gastrointestinal and cardiovascular treatments, and some used in the treatment of Parkinson’s disease. As it is an ongoing investigation, the names of the companies or individuals involved have not been revealed.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI